These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Pharmacokinetics of pefloxacin in renal insufficiency. Montay G; Jacquot C; Bariety J; Cunci R Eur J Clin Pharmacol; 1985; 29(3):345-9. PubMed ID: 3865778 [TBL] [Abstract][Full Text] [Related]
43. [Pharmacokinetic study of pefloxacin in 37 hospital patients under resuscitation]. Chomarat M; Joulie V; Fournier G; Bouletreau P; Flandrois JP Pathol Biol (Paris); 1985 Jun; 33(5 Pt 2):539-41. PubMed ID: 3911151 [TBL] [Abstract][Full Text] [Related]
44. The diffusion of pefloxacin into bone and the treatment of osteomyelitis. Dellamonica P; Bernard E; Etesse H; Garraffo R J Antimicrob Chemother; 1986 Apr; 17 Suppl B():93-102. PubMed ID: 3086280 [TBL] [Abstract][Full Text] [Related]
45. Pharmacokinetics and bacteriological efficacy of N-formimidoyl thienamycin in experimental Escherichia coli meningitis. Patamasucon P; McCracken GH Antimicrob Agents Chemother; 1982 Mar; 21(3):390-2. PubMed ID: 7049073 [TBL] [Abstract][Full Text] [Related]
47. [Biotransformation of selected gyrase inhibitors]. Borner K; Lode H Infection; 1986; 14 Suppl 1():S54-9. PubMed ID: 3007367 [TBL] [Abstract][Full Text] [Related]
48. Ceftriaxone for meningitis, due to Escherichia coli, which developed during tobramycin therapy. Shaw DW; Ali RM; Beeching NJ; Lang SD N Z Med J; 1984 Jul; 97(760):500. PubMed ID: 6089061 [No Abstract] [Full Text] [Related]
50. Comparative activities of norfloxacin and fleroxacin in experimental infections due to Salmonella typhimurium and Escherichia coli. Hof H; Fabrig J J Antimicrob Chemother; 1988 Oct; 22 Suppl D():123-7. PubMed ID: 3144530 [TBL] [Abstract][Full Text] [Related]
51. Evaluation of FCE 22101 in experimental meningitis caused by Escherichia coli and Streptococcus pneumoniae. Dworkin RJ; Tureen JH; Kennedy SL; Sachdeva M; Sande MA J Antimicrob Chemother; 1989 Mar; 23 Suppl C():143-8. PubMed ID: 2659571 [TBL] [Abstract][Full Text] [Related]
52. Effectiveness of cefotaxime in gram-negative meningitis. LeFrock JL; Molavi A; Smith B; Black P; Rosenberg M; Rolston K; Brodner R; Chandrasekar P; Henao L; Kannangara DW Neurosurgery; 1984 Nov; 15(5):679-82. PubMed ID: 6095133 [TBL] [Abstract][Full Text] [Related]
53. Pharmacokinetics of pefloxacin after repeated intravenous and oral administration (400 mg bid) in young healthy volunteers. Frydman AM; Le Roux Y; Lefebvre MA; Djebbar F; Fourtillan JB; Gaillot J J Antimicrob Chemother; 1986 Apr; 17 Suppl B():65-79. PubMed ID: 3458699 [TBL] [Abstract][Full Text] [Related]
54. [Treatment of purulent meningitis in the child using Cefotaxime]. Borderon JC; Despert F; Santini JJ; Laugier J Pediatrie; 1985 Jun; 40(4):291-9. PubMed ID: 3909093 [TBL] [Abstract][Full Text] [Related]
55. Bacterial meningitis. Rational selection and use of antibacterial drugs. Whitby M; Finch R Drugs; 1986 Mar; 31(3):266-78. PubMed ID: 3519175 [TBL] [Abstract][Full Text] [Related]
56. The efficacy of pefloxacin in comparison to gentamicin in the treatment of experimentally induced peritonitis in rats. Nord CE; Edlund C; Lahnborg G J Antimicrob Chemother; 1986 Apr; 17 Suppl B():59-63. PubMed ID: 2872197 [TBL] [Abstract][Full Text] [Related]
57. Clinical conferences at the Johns Hopkins Hospital. Gram-negative bacillary meningitis. Johns Hopkins Med J; 1978 Aug; 143(2):60-3. PubMed ID: 355698 [No Abstract] [Full Text] [Related]